Active	Status	Sponsor type	Region	Phase	Filter
2 Active 3 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
naronapride (ATI-7505) / Renexxion
2021-002254-86: Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose	Not yet recruiting	2	320	Europe	Naronapride 10 mg film-coated tablets, Naronapride 20 mg film-coated tablets, Naronapride 40 mg film-coated tablets, [N/A], N/A, Film-coated tablet	Dr. Falk Pharma GmbH, DR. FALK PHARMA GMBH, Dr. Falk Pharma GmbH	idiopathic or diabetic gastroparesis, stomach cannot empty food in the normal way, Diseases [C] - Digestive System Diseases [C06]
MOVE-IT, NCT05621811: Different Doses of Naronapride vs. Placebo in Gastroparesis	Recruiting	2	320	Europe, US	Naronapride, Placebo	Dr. Falk Pharma GmbH	Gastroparesis	01/25	04/25
Undisclosed IBD therapeutic / Renexxion
No trials found